SCVC

Forefront RF is a fabless semiconductor company.

Nebu-Flow is focused on developing advanced nebulizers aimed at improving the delivery of treatments for patients with respiratory disorders. The company has created a novel pulmonary drug-delivery technology that facilitates the efficient administration of difficult-to-nebulize medications directly to the lungs. This includes both existing formulations and innovative therapeutics such as biologics, nanomedicines, and vaccines. By enhancing the delivery of these treatments, Nebu-Flow aims to support medical professionals in addressing and curing various respiratory diseases.

OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).

Forefront RF is a fabless semiconductor company.

Carbometrics is a specialized chemistry company focused on the development of glucose-binding molecules aimed at improving the lives of individuals with diabetes. Leveraging over 20 years of research led by Professor Anthony Davis at the University of Bristol, Carbometrics designs, synthesizes, and modifies carbohydrate-binding molecules to create a highly accurate and robust glucose sensing platform. The company's primary objective is to utilize its glucose-binding molecule technology to develop a market-leading Continuous Glucose Monitoring (CGM) solution. Founded by the team behind the successful company Ziylo, which was acquired by Novo Nordisk, Carbometrics aims to advance diabetes management through innovative monitoring solutions.

Cytoseek Limited, founded in 2017 and based in Bristol, United Kingdom, specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. As a spinout from the University of Bristol, the company utilizes a unique cell membrane augmentation technology that enhances cell therapies by adding new functionalities, such as tissue-specific targeting and improved cell survivability. Currently, Cytoseek is conducting proof of principle studies to validate the effectiveness of its therapies and is actively seeking partnerships with other cell therapy companies to advance these treatments into clinical settings, ultimately aiming to improve human health.